Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction
Abstract
Irbesartan belongs to the group of the angiotensin II AT1 receptor blockers. In preclinical trials, beneficial effect of irbesartan on renal function has been documented which is presumably mediated through pleiotropic mechanisms (antioxidative, anti-inflammatory, antiatherosclerotic effect, inhibition of glomerular basal membrane thickening, inhibition of proximal tubular cells hypertrophication etc.).
Apart from this, irbesartan has been shown to have beneficial effect on glucose tolerance as well. Consequently, benefit of irbesartan in patients with arterial hypertension, diabetes mellitus and nephropathy has been demonstrated in clinical trials, particularly the IRMA-2 and IDNT.
In the Czech Republic, irbesartan has been registered for the treatment of essential arterial hypertension as well as the treatment of kidney disease in adults with arterial hypertension and type 2 diabetes mellitus.